secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000950170-24-118586
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025
----------------------------------------------------------------------------

- Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
- Cash, cash equivalents and marketable securities $203.7M as of Sep 30, 2024; projected runway into 2026.
- Nomlabofusp program update in mid-Dec with safety, PK, frataxin data from 25 mg daily OLE study.
- PK run-in study in adolescents on track by year-end 2024; global confirmatory study planned mid-2025.
- BLA submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/0000950170-24-118586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/lrmr-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-118586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer